clinical phase studies performed swiss institute nuclear research sin february NUMBER NUMBER patients accepted pion treatment end NUMBER treated malignant glioma high dose pion irradiation substantial influence radioresistance expected increased radiation quality contribution high let particles pion capture possibility target volume shaping dose distribution related dynamic conformation technique patients treatment followed dose escalation program total doses cgy fraction sizes NUMBER NUMBER cgy NUMBER isodose minimum target dose treatment times NUMBER NUMBER weeks patients received accelerated treatment NUMBER cgy days patients eligible NUMBER astrocytoma clinical aggressive behaviour NUMBER anaplastic astrocytoma median age NUMBER years NUMBER patients glioblastoma median age NUMBER years patients tumour resection NUMBER patients stereotactic biopsy patients divided groups according total dose fourth group received accelerated treatment statistically significant difference median survival rate groups NUMBER months patients NUMBER months glioblastoma patients radiation necrosis demyelination NUMBER patients NUMBER recraniotomies NUMBER autopsies patients clearly identifiable tumour cells demonstrated nmr findings showed oedema stimulated tumour necrosis tumour progression findings dose escalation programs shaping target volume close tumour contraindicated fifty spot scan NUMBER NUMBER NUMBER NUMBER non glioblastoma tumour surrounding ii NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER total subtotal NUMBER NUMBER